## CLAIMS

1. A compound represented by the following formula (I):

$$A[B\text{-}(C)_v]_w \quad (I),$$

wherein:

A is a photoprotective moiety,

B is a linker,

C is a functional group,

v is an integer from 1 to 2000, and

w is an integer from 1 to 6.

2. The compound according to claim 1, wherein the photoprotective moiety A is derived from bemotrizinol, diethylamino hydroxybenzoyl hexyl benzoate, bisdisulizole disodium, meradimate, terephtalylidene dicamphor sulfonic acid, bisoctrizole, oxybenzone, sulisobenzone, iscotrizinol, octinoxate, octisalate, octyltriazone, padimate O, homosalate, amiloxate, octocrylene, PEG-25 PABA, ensulizole, trolamine salicylate, cinoxate, benzophenone-9, dioxybenzone, avobenzone, enzacamene, diethylhexyl naphthalate, diethylhexyl syringylidene, tetramethylhydroxy piperidinol, sodium benzotriazolyl butylphenol sulfonate, benzotriazole dodecyl p-cresol sulfonate, polyester-8, acrylates copolymer, butyloctyl salicylate, bis(cyano butylacetate) anthracenediylidene, dimethylcapramide, or ethyl hexyl methoxycrylene, preferably from bemotrizinol, diethylamino hydroxybenzoyl hexyl benzoate, terephtalylidene dicamphor sulfonic acid, sulisobenzone, octisalate, octocrylene, ensulizole, avobenzone, polyester-8, bisdisulizole disodium, meradimate, oxybenzone-3, iscotrizinol, octanoate, octyltriazone, padimate O, cinoxate, benzophenone-9, or dioxybenzone, more preferably from bemotrizinol, diethylamino hydroxybenzoyl hexyl benzoate, terephtalylidene dicamphor sulfonic acid, or octocrylene.

3. The compound according to claim 1 or 2, wherein the linker B is a linear polymer, a branched polymer, a hyperbranched polymer, a dendrimer, or a residue thereof.

4. The compound according to any one of claims 1 to 3, wherein the linker B further comprises at least one $-S(O)_2-$ group.

5. The compound according to any one of claims 1 to 4, wherein the linker B is represented by the following formula (II):

$$-[Y-(CH_2)_q-(O-CH_2-CH_2)_p-Z-(CH_2)_s]_k- \qquad (II),$$

















wherein:









- Y is selected from -O-, -NH-, and -C(O)-;
  q is an integer from 0 to 35, preferably from 0 to 12, more preferably from 0 to 6;
  with the proviso that, when Y is -O-, q is different from 0;
  p is an integer from 0 to 250, preferably from 0 to 50, more preferably from 0 to 12; and
  p+q is different from 0; or
- $Y-(CH_2)_q$ may form a heterocycle selected in the group consisting of a pyrrolidinyl and piperidinyl; and
  p is 0;
- Z is selected from a single bond, -NH-, -O-, -NH-C(O)-, -S-, and $-S(O)_2-$;
- s is an integer from 0 to 6; and
- k is an integer from 1 to 4, preferably from 1 to 2.


6. The compound according to claim 5, wherein Z is selected from -NH-, -O-, -NH-C(O)-, -S-, and $-S(O)_2-$.


7. The compound according to any one of claims 1 to 6, wherein the functional group C is chosen from an aldehyde, an acetal, thiocetal, a thiol, a maleimide, a Mickael acceptor, a vinylsulfone, a disulfanylpyridine, a sulfonylaziridine, an epoxide, a haloacetyl, an isocyanate, an isothiocyanate, a N-hydroxysuccinimide ester, a N-hydroxysulfosuccinimide ester, a hydroxy, an amino, an ammonium, a guanidinium, an imidocarbonate, a carboxylic acid, a carboxylic ester, an anhydride, a sulfonic acid, folic acid, biotin, streptavidin, avidin, antibodies, and single chain antibodies or fragments thereof, and derivatives thereof, preferably from a thiol, an acetal, a maleimide, a vinylsulfone, a disulfanylpyridine, a guanidinium, folic acid, biotin, and derivatives thereof, more preferably C is a maleimide or a derivative thereof.


8. The compound according to any one of claims 1 to 5 and 7, wherein the moiety $B-(C)_v$ is represented by one of the following formulae:



,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,



,

,

,

,

,

5 ,

,

,



,



,



,


,



,



,



,



,


5 or



,



,


,


,


,


, or


,

wherein, in each formula,

n is independently an integer from 0 to 250, preferably from 0 to 50, more preferably from 0 to 12, and

t is independently an integer from 0 to 30, preferably from 0 to 12.

9. The compound according to claim 1, wherein said compound is selected from the group consisting of:

- 2,2'-[6-(4-Methoxyphenyl)-1,3,5-triazine-2,4-diyl]bis[5-[(3-propyl-1H-pyrrole-2,5-dione) oxy]phenol];
- 2-[4-(diethylamino)-2-hydroxybenzoyl]-benzoic acid, 6-maleimido-1-hexanol ester;
- 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoic acid, 2-(2-pyridinyldisulfanyl)ethanol ester;
- 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoic acid, N-[5-(-2,5-dihydro-1H-pyrrole-2,5-dione)pentyl]amide;
- 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoic acid, N-[4-(1,3-dioxolan-2-yl)butane] amide;
- 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoic acid, biotine-PEG2-amide;
- N-[4-(-2,5-dihydro-1H-pyrrole-2,5-dione)butyl]salicylamide;
- 2-Cyano-3,3-diphenylpropenoic acid, 6-maleimido-1-hexanol ester;
- 2-Cyano-3,3-diphenylpropenoic acid, folate-PEG-1k ester;
- 2-Cyano-3,3-diphenylpropenoic acid, 1,3-Bis(vinylsulfonyl)-1-propanol ester;
- 2-Phenyl-1H-benzimidazol-5-(biotine-PEG8-N-ethyl)sulfonamide;
- 2-Hydroxy-4-methoxybenzophenone-5-(biotine-PEG8-N-ethyl)sulfonamide;
- [N-(2-Cyano-3,3-diphenylpropenoyl)-piperidin-4-ylsulfonyl]acetic acid;
- N-[(2-hydroxybenzoyl)-piperidin-4-ylsulfonyl] acetic acid;
- (3-(2H-benzo[d][1,2,3]triazol-2-yl)-5(tert-butyl)-4-hydroxyphenyl)propanoic, N-[(4-piperidin-4-ylsulfonyl)acetic] amide;
- 2-[4-(diethylamino)-2-hydroxybenzoyl]-benzoic acid, 2-[2-[3-(2,5-dioxopyrrol-1-yl) propanoylamino]ethoxy]ethyl ester;
- 2-[4-(diethylamino)-2-hydroxy-benzoyl]benzoic acid, 2-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]ethyl ester;
- 2-cyano-N-[2-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]ethyl]-3,3-diphenyl-prop-2-enamide;
- 2-cyano-3,3-diphenyl-prop-2-enoate, 2-[2-[3-(2,5-dioxopyrrol-1-yl)propanoylamino] ethylsulfonyl]ethyl ester;
- 3-(2,5-dioxopyrrol-1-yl)-N-[2-[[(3Z)-3-[[4-[(Z)-[4-[2-[3-(2,5-dioxopyrrol-1-yl)propanoyl amino]ethylsulfamoylmethyl]-7,7-dimethyl-3-oxo-norbornan-2-ylidene]methyl]phenyl] methylene]-7,7-dimethyl-2-oxo-norbornan-1-yl]methylsulfonylamino] ethyl]propenamide;
- -3-(2,5-dioxopyrrol-1-yl)-N-[3-[4-[4-[4-[3-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]propoxy]-2-hydroxy-phenyl]-6-(4-methoxyphenyl)-1,3,5-triazin-2-yl]-3-hydroxy-phenoxy]propyl]propanamide; and

-3-(2,5-dioxopyrrol-1-yl)-N-[2-[2-[2-[2-[4-[4-[4-[2-[2-[2-[2-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]ethoxy]ethoxy]ethoxy]ethoxy]-2-hydroxy-phenyl]-6-(4-methoxyphenyl)-1,3,5-triazin-2-yl]-3-hydroxy-phenoxy]ethoxy]ethoxy]ethoxy]ethyl]propanamide.

10. A composition comprising at least one compound of formula (I) as defined in any one of claims 1 to 9 and at least one excipient.

11. The composition according to claim 10, wherein said composition is a sunscreen composition or a cosmetic composition.

12. A cosmetic use of a composition as defined in claim 10, for combatting and/or reducing the signs of cutaneous ageing, such as the formation of wrinkles and/or fine lines, skin sagging, loss of firmness, loss of radiance and/or evenness of the complexion, and/or for reinforcing the skin barrier.

13. A kit comprising:

- a composition as defined in claim 10,
- a washing composition, preferably a powder, a shampoo, a soap, a lotion, a solution, a solid, a scrubbing, a mousse, a foam, a syndet, a gel, a shower gel, a spray, a mist, a wax, a strip, or a woven or non-woven fabric, and
- optionally an instruction guide.

14. The composition according to claim 10, wherein said composition is a pharmaceutical or a veterinary composition.

15. Use of a composition as defined in claim 14 in the manufacture of a medicament for treating and/or preventing a skin, mucosa, eye cornea, or skin appendage disease or condition, preferably said skin, mucosa, eye cornea, or skin appendage disease or condition is chosen from lipodystrophy, keloid scars, acne, psoriasis, atopic dermatitis, actinic keratosis, rosacea, melasma, melanoma, Merker cell carcinoma, basal cell carcinoma, squamous cell carcinoma, scar treatments, wound healing, alopecia, vitiligo, urticaria (hives), cold sores, impetigo, eczema, rashes dermatitis, ichthyosis, warts, blisters, pruritus, gangrene, bruises, pustules, bacterial skin infections like leprosy, carbuncles, cellulitis, impetigo, fungal infections like

Athlete's foot (intertrigo) and sporotrichosis, fungal nail infections, viral infection like herpes, sunburns, lice, scabies, pressure ulcer disinfection, and pressure ulcer healing.

16. The composition according to claim 10, 11, or 12, or the use according to claim 15, wherein said composition is a topical composition, preferably said composition is in the form of a suspension, a cream, a spray, an aerosol, a butter, a stick, a gel, an ointment, a lotion, a solution, a solid, an emulsion, a micro-emulsion, an oil, a lyophilizate, a milk, a powder, a paste, a wax, a mousse, a patch, a film, a micelle, a liposome, or a foam.

17. A use of at least one compound as defined in any one of claims 1 to 9 for reducing photodegradation and/or photoinstability of a pharmaceutical active ingredient or a cosmetic.

18. A material comprising a support and at least one compound as defined in any one of claims 1 to 9, said compound being adhered to said support which is preferably a natural or synthetic polymeric support, a natural or synthetic fiber support, a stone, a metal, a plastic, a rubber or a glass support.